

- Press release -

LFB PRESENTS ITS RAISON D'ÊTRE: "LFB, EXPERTISE COMMITTED TO LIFE"

Les Ulis (France), April 29th, 2024 – LFB officially presents its Raison d'Être: "LFB, expertise committed to life". As experts in plasma-derived therapies, LFB is an essential link between donors and patients, thanks to its know-how and its commitment to patients. Invested with a public health mission, a pillar of French health sovereignty, and a recognized international actor, LFB develops, manufactures, and distributes biopharmaceuticals to improve patients' lives in responsible and sustainable ways.

For Jacques Brom, CEO of LFB: "Our Raison d'Être defines the company's contribution to society. It is the compass that will guide our actions from now on: "LFB, expertise committed to life". I would like to use this opportunity to thank all of LFB's employees, in France and abroad, as well as all of our external stakeholders, who have been extensively involved in building our Raison d'Être".

Our Raison d'Être is born from the contributions of those who bring LFB to life every day

LFB consulted all employees worldwide to build together the *Raison d'Être*. 64% of employees contributed through a digital survey and expressed their vision of LFB and their experience within the company. This high mobilization rate reflects employees who are deeply involved in the LFB's projects and commitment to LFB's future. LFB's partners, including patient and blood donor associations, healthcare professionals, clients, suppliers, banks, and members of the LFB's Board of Directors, also had a tremendous contribution.

"LFB, expertise committed to life": the meaning of our Raison d'Être

- **Firstly, expertise** with therapies derived from living organisms, which makes all the difference for patients. Expertise also encompasses the expertise of employees who contribute to making LFB a recognized and essential player thanks to a unique know-how in biopharmaceuticals.
- **Secondly, commitment.** Commitment was, in fact, highlighted as a key value of LFB during the consultation. The sense of commitment is deeply rooted within each employee, as they are all strongly driven by the desire to serve patients.
- **Finally, a commitment to life,** drives each and every LFB employee, all of whom are aware that therapies produced by LFB enable the care of patients with serious and often rare diseases, in France and around the world.

The *Raison d'Être* unifies the vision of different businesses within LFB and orients LFB's operations to continue having a concrete impact on patients and in the world. As one of the first leaders in the French pharmaceutical sector to formally adopt a *Raison d'Être*, LFB sees the *Raison d'Être* as an essential prerequisite to becoming a mission-driven company and a necessary first step to continue its work in this direction.

For its 30th anniversary in 2024, LFB lays a foundation to extend its next generation CDMO (Contract Development Manufacturing Organization) bioproduction plant in Alès (France) and to inaugurate its new industrial site in Arras (France) by the end of the year. The Arras plant, already employing 300 people, will allow LFB to triple its biopharmaceutical production capacity to meet the growing demand from patients.



About LFB

LFB is a biopharmaceutical group that develops, manufactures, and markets plasma-derived therapies and recombinant proteins for the treatment of patients with serious and often rare diseases. Created in France in 1994, LFB today is a leading European company providing plasma-derived medicinal products to healthcare professionals. Its mission is to offer patients new treatment options for unmet needs in three major therapeutic areas: immunology, haemostasis and intensive care. LFB's current market portfolio includes 15 biomedicinal products sold in about 30 countries.

For more information about LFB, go to: www.groupe-lfb.com

LFB Contact:

Didier Véron – Executive Vice President Corporate Affairs

Tel: +33 (0)1.69.82.72.97 ou +33 (0)6.08.56.76.54

verondidier@lfb.fr